Get the Stockscreener App
7.67
3.76%
-0.30
After Hours:
7.60
-0.07
-0.91%
Lyra Therapeutics Inc stock is traded at $7.67, with a volume of 64,455.
It is down -3.76% in the last 24 hours and up +19.66% over the past month.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$7.97
Open:
$7.8
24h Volume:
64,455
Relative Volume:
2.23
Market Cap:
$12.61M
Revenue:
$1.47M
Net Income/Loss:
$-97.61M
P/E Ratio:
-5.1477
EPS:
-1.49
Net Cash Flow:
$-80.90M
1W Performance:
+9.57%
1M Performance:
+19.66%
6M Performance:
+80.68%
1Y Performance:
-31.12%
1-Day Range:
$7.5052
$8.0499
1-Week Range:
$6.70
$8.7478
52-Week Range:
$3.8101
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617-373-4600
Address
480 ARSENAL WAY, WATERTOWN, MA
Compare LYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
7.67 | 13.11M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-07-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-07-24 | Downgrade | Jefferies | Buy → Hold |
| May-06-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-23 | Resumed | BTIG Research | Buy |
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
Regression analysis insights on Lyra Therapeutics Inc. performanceWeekly Market Report & Safe Capital Growth Tips - newser.com
Using data models to predict Lyra Therapeutics Inc. stock movement2025 Technical Overview & Fast Momentum Entry Tips - newser.com
Published on: 2025-10-09 05:19:19 - newser.com
Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate - Stocktwits
Lyra Therapeutics Announces Clinical Plan for LYR-210 and - GlobeNewswire
Lyra Therapeutics outlines path to NDA for CRS treatment - Investing.com
Lyra Therapeutics (LYRA) Advances CRS Treatment with Positive Tr - GuruFocus
Lyra Therapeutics outlines path to NDA for CRS treatment By Investing.com - Investing.com Australia
Lyra unveils clinical plan for LYR-210, to present late-stage sinusitis trial data - MarketScreener
Lyra Therapeutics Announces Clinical Plan for LYR-210 Following Positive ENLIGHTEN 2 Results and Upcoming FDA Engagement - Quiver Quantitative
Lyra Therapeutics, Inc. Announces Clinical Plan for Lyr-210 and Late-Breaking Oral Presentation of Phase 3 Enlighten 2 Study - MarketScreener
Multi asset correlation models including Lyra Therapeutics Inc.Weekly Profit Analysis & AI Powered Market Entry Strategies - newser.com
What the charts say about Lyra Therapeutics Inc. todayJuly 2025 Selloffs & Intraday High Probability Setup Alerts - newser.com
Using Python tools to backtest Lyra Therapeutics Inc. strategiesMarket Volume Summary & Real-Time Volume Triggers - newser.com
Is Lyra Therapeutics Inc. stock supported by strong cash flowsLayoff News & Free Weekly Chart Analysis and Trade Guides - newser.com
What analysts say about Lyra Therapeutics Inc stockRisk Adjusted Returns & Free Stock Price Trend Analysis - earlytimes.in
Is Lyra Therapeutics Inc. stock ready for a breakoutPrice Action & Growth Focused Investment Plans - newser.com
Goldman Sachs Group Inc. Sells 185,314 Shares of Lyra Therapeutics, Inc. $LYRA - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Stock Price Up 0.5% – Here’s Why - Defense World
Is Lyra Therapeutics Inc a good long term investmentUtilities Sector Analysis & Target Triple-Digit Stock Opportunities - earlytimes.in
What drives Lyra Therapeutics Inc stock priceEarnings Miss Alerts & Capital Allocation Recommendations - earlytimes.in
US Market Recap: How much upside does Lyra Therapeutics Inc haveGDP Growth & Trade Opportunity Analysis - خودرو بانک
Tech Rally: Is Lyra Therapeutics Inc stock a good pick for beginnersMarket Performance Report & Verified Technical Signals - khodrobank.com
Quantitative breakdown of Lyra Therapeutics Inc. recent moveJuly 2025 Closing Moves & High Accuracy Swing Entry Alerts - newser.com
Market Moves: Should I hold or sell Lyra Therapeutics Inc nowEarnings Summary Report & Low Risk High Reward Trade Ideas - خودرو بانک
Live market analysis of Lyra Therapeutics Inc.July 2025 Earnings & Risk Adjusted Buy and Sell Alerts - newser.com
Top chart patterns to watch in Lyra Therapeutics Inc.IPO Watch & Safe Capital Growth Trade Ideas - newser.com
Can swing trading help recover from Lyra Therapeutics Inc. lossesBull Run & Technical Entry and Exit Alerts - newser.com
Is Lyra Therapeutics Inc. a candidate for recovery playJuly 2025 Trends & Weekly Setup with ROI Potential - newser.com
Travel Stocks: Will Lyra Therapeutics Inc. face regulatory challenges2025 Volume Leaders & Fast Exit and Entry Strategy Plans - خودرو بانک
Macro Review: Why is AGNCL stock going up2025 Dividend Review & Fast Gain Swing Alerts - خودرو بانک
Trading Recap: Can Lyra Therapeutics Inc outperform under higher oil prices2025 Buyback Activity & Safe Capital Investment Plans - خودرو بانک
Weekly Earnings: Should I trade or invest in Koninklijke Philips N.V. Depositary ReceiptJuly 2025 Spike Watch & Reliable Breakout Forecasts - خودرو بانک
Sectors Review: Can Lyra Therapeutics Inc outperform under higher oil pricesMarket Volume Summary & Consistent Income Trade Recommendations - خودرو بانک
ETF Watch: Can Kennametal Inc. lead its sector in growthTrade Volume Summary & Daily Entry Point Alerts - خودرو بانک
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lyra Therapeutics Inc Stock (LYRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cavalier Jason | Chief Financial Officer |
Jul 10 '25 |
Sale |
8.91 |
684 |
6,094 |
519,316 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):